Hit to lead (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Hit to lead" in English language version.

refsWebsite

Global rank English rank

6doi.org

2^nd place

5nih.gov

4^th place

2acs.org

1,248^th place

1,104^th place

2worldcat.org

5^th place

1books.google.com

3^rd place

1semanticscholar.org

11^th place

8^th place

1nytimes.com

7^th place

1efmc.info

low place

acs.org (Global: 1,248^th place; English: 1,104^th place)

pubs.acs.org

Beckers, Maximilian; Fechner, Nikolas; Stiefl, Nikolaus (2022-12-12). "25 Years of Small-Molecule Optimization at Novartis: A Retrospective Analysis of Chemical Series Evolution". Journal of Chemical Information and Modeling. 62 (23): 6002–6021. doi:10.1021/acs.jcim.2c00785. ISSN 1549-9596. PMID 36351293.
Brown, Dean G. (2023-06-08). "An Analysis of Successful Hit-to-Clinical Candidate Pairs". Journal of Medicinal Chemistry. 66 (11): 7101–7139. doi:10.1021/acs.jmedchem.3c00521. ISSN 0022-2623. PMID 37224022.

books.google.com (Global: 3^rd place; English: 3^rd place)

Fruber M, Narjes F, Steele J (2013). "Lead Generation". In Davis A, Ward SE (eds.). Handbook of Medicinal Chemistry: Principles and Practice. RSC Books. pp. 505–528. ISBN 978-1849736251.

doi.org (Global: 2^nd place; English: 2^nd place)

Deprez-Poulain R, Deprez B (2004). "Facts, figures and trends in lead generation". Current Topics in Medicinal Chemistry. 4 (6): 569–80. doi:10.2174/1568026043451168. PMID 14965294.
Keseru GM, Makara GM (Aug 2006). "Hit discovery and hit-to-lead approaches". Drug Discovery Today. 11 (15–16): 741–8. doi:10.1016/j.drudis.2006.06.016. PMID 16846802.
Bleicher KH, Böhm HJ, Müller K, Alanine AI (May 2003). "Hit and lead generation: beyond high-throughput screening". Nature Reviews. Drug Discovery. 2 (5): 369–78. doi:10.1038/nrd1086. PMID 12750740. S2CID 4859609.
Cockbain J (2007). "Intellectual property rights and patents". In Triggle JB, Taylor DJ (ed.). Comprehensive Medicinal Chemistry. Vol. 1 (2nd ed.). Amsterdam: Elsevier. pp. 779–815. doi:10.1016/B0-08-045044-X/00031-6. ISBN 978-0-08-045044-5.
Beckers, Maximilian; Fechner, Nikolas; Stiefl, Nikolaus (2022-12-12). "25 Years of Small-Molecule Optimization at Novartis: A Retrospective Analysis of Chemical Series Evolution". Journal of Chemical Information and Modeling. 62 (23): 6002–6021. doi:10.1021/acs.jcim.2c00785. ISSN 1549-9596. PMID 36351293.
Brown, Dean G. (2023-06-08). "An Analysis of Successful Hit-to-Clinical Candidate Pairs". Journal of Medicinal Chemistry. 66 (11): 7101–7139. doi:10.1021/acs.jmedchem.3c00521. ISSN 0022-2623. PMID 37224022.

efmc.info (Global: low place; English: low place)

"Hit Generation".

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Deprez-Poulain R, Deprez B (2004). "Facts, figures and trends in lead generation". Current Topics in Medicinal Chemistry. 4 (6): 569–80. doi:10.2174/1568026043451168. PMID 14965294.
Keseru GM, Makara GM (Aug 2006). "Hit discovery and hit-to-lead approaches". Drug Discovery Today. 11 (15–16): 741–8. doi:10.1016/j.drudis.2006.06.016. PMID 16846802.
Bleicher KH, Böhm HJ, Müller K, Alanine AI (May 2003). "Hit and lead generation: beyond high-throughput screening". Nature Reviews. Drug Discovery. 2 (5): 369–78. doi:10.1038/nrd1086. PMID 12750740. S2CID 4859609.
Beckers, Maximilian; Fechner, Nikolas; Stiefl, Nikolaus (2022-12-12). "25 Years of Small-Molecule Optimization at Novartis: A Retrospective Analysis of Chemical Series Evolution". Journal of Chemical Information and Modeling. 62 (23): 6002–6021. doi:10.1021/acs.jcim.2c00785. ISSN 1549-9596. PMID 36351293.
Brown, Dean G. (2023-06-08). "An Analysis of Successful Hit-to-Clinical Candidate Pairs". Journal of Medicinal Chemistry. 66 (11): 7101–7139. doi:10.1021/acs.jmedchem.3c00521. ISSN 0022-2623. PMID 37224022.

nytimes.com (Global: 7^th place; English: 7^th place)

Ezekiel J. Emanuel (9 September 2015). "The Solution to Drug Prices". New York Times. On average, only one in every 5,000 compounds that drug companies discover and put through preclinical testing becomes an approved drug. Of the drugs started in clinical trials on humans, only 10 percent secure F.D.A. approval. ...

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Bleicher KH, Böhm HJ, Müller K, Alanine AI (May 2003). "Hit and lead generation: beyond high-throughput screening". Nature Reviews. Drug Discovery. 2 (5): 369–78. doi:10.1038/nrd1086. PMID 12750740. S2CID 4859609.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Beckers, Maximilian; Fechner, Nikolas; Stiefl, Nikolaus (2022-12-12). "25 Years of Small-Molecule Optimization at Novartis: A Retrospective Analysis of Chemical Series Evolution". Journal of Chemical Information and Modeling. 62 (23): 6002–6021. doi:10.1021/acs.jcim.2c00785. ISSN 1549-9596. PMID 36351293.
Brown, Dean G. (2023-06-08). "An Analysis of Successful Hit-to-Clinical Candidate Pairs". Journal of Medicinal Chemistry. 66 (11): 7101–7139. doi:10.1021/acs.jmedchem.3c00521. ISSN 0022-2623. PMID 37224022.

Hit to lead (English Wikipedia)

acs.org (Global: 1,248th place; English: 1,104th place)

pubs.acs.org

books.google.com (Global: 3rd place; English: 3rd place)

doi.org (Global: 2nd place; English: 2nd place)